EFFECTS OF ALENDRONATE ON BONE LOSS IN PREMENOPAUSAL AND POSTMENOPAUSAL HYPERTHYROID WOMEN TREATED WITH METHIMAZOLE

Authors
LUPOLI G NUZZO V DICARLO C AFFINITO P VOLLERY M VITALE G CASCONE E ARLOTTA F NAPPI C
Citation
G. Lupoli et al., EFFECTS OF ALENDRONATE ON BONE LOSS IN PREMENOPAUSAL AND POSTMENOPAUSAL HYPERTHYROID WOMEN TREATED WITH METHIMAZOLE, Gynecological endocrinology, 10(5), 1996, pp. 343-348
Citations number
38
Categorie Soggetti
Endocrynology & Metabolism","Obsetric & Gynecology
Journal title
Gynecological endocrinology → ACNP
ISSN journal
09513590
Volume
10
Issue
5
Year of publication
1996
Pages
343 - 348
Database
ISI
SICI code
0951-3590(1996)10:5<343:EOAOBL>2.0.ZU;2-#
Abstract
High levels of thyroid hormones accelerate bone turnover. The aim of t he present study was to evaluate the effects of treatment with alendro nate in patients affected by hyperthyroidism and osteoporosis. We stud ied 40 hyperthyroid patients with bone loss, divided into two groups a ccording to menopausal state. Before treatment and after 6 and 12 mont hs, serum 1 thyroid hormones levels, sevum osteocalcin level and bone mineral density were evaluated. In all patients we observed an increas e in bone mineral density after treatment with alendronate, and a corr esponding decrease in serum osteocalcin level.